Skip to main content
. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497

Figure 4. CD46 ADC potently inhibits mCRPC xenograft growth in vivo.

Figure 4

(A) Large-sized (~500 mm3) LNCaP-C4-2B xenograft was treated with YS5-MC-vc-PAB-MMAF for a total of 4 doses at 5 mg/kg. Three control arms were included: vehicle only (PBS), naked antibody (YS5), and control ADC based on a nonbinding IgG1 (Ctrl IgG-MC-vc-PAB-MMAF). Injection days are indicated by black triangles and dashed lines. (B) Body weight assessment during the course of the experiment shown in A. (C) Study design of ADC treatment of intrafemorally grafted mCRPC. LNCaP-C4-2B engineered to express the firefly luciferase gene was injected intrafemorally. Graft was allowed to establish and grow for 7 days, and CD46 ADC was injected at 5 mg/kg for a total of 4 doses. (D) Bioluminescence imaging (BLI) showed that CD46 ADC potently eliminates intrafemorally grafted mCRPC cell line xenograft model. (E) Quantification of BLI (CD46 ADC, i.e., YS5-MC-vc-PAB-MMAF, vs. control ADC, i.e., Ctrl IgG-MC-vc-PAB-MMAF) on day 2 (no significant difference), day 30 (**P < 0.01, P = 0.0079), and day 65 (**P < 0.01, P = 0.0079). Mann-Whitney U nonparametric test, unpaired, 2-tailed.